Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Engineered exosomes with KrasG12D specific siRNA in pancreatic cancer: a phase I study with immunological correlates

Open access

Abstract

Oncogenic KRAS is amongst the key genetic drivers for initiation and maintenance of pancreatic ductal adenocarcinoma (PDAC). Here, we show that engineered exosomes with KrasG12D specific siRNA (iExoKrasG12D) reveal a biodistribution in pancreas with negligible toxicity in preclinical studies in mice and Rhesus macaques. Clinical testing of iExoKrasG12D in the iEXPLORE (iExoKrasG12D in Pancreatic Cancer) Phase I study employed a non-randomized single-arm classical 3 + 3 dose escalation design (Phase Ia), followed by an accelerated titration design (Phase Ib) (NCT03608631). The primary outcomes included safety, tolerability and target engagement, and the secondary outcomes aimed to assess disease control. Patients with advanced metastatic disease were enrolled after failure of multiple lines of therapy. iExoKrasG12D therapy was well-tolerated: the primary outcomes were met with iExoKrasG12D showing no dose-limiting toxicity. The maximum tolerated dose was not reached even at the highest dose. In some cases, iExoKrasG12D therapy was associated with stable disease response (secondary outcome). Downregulation of KRASG12D DNA and suppression of phospho-Erk was documented together with an increase in intratumoral CD8+ T cells following treatment. The CD8+ T cell recruitment priming by iExoKrasG12D informed on potential efficacy of immune checkpoint therapy and lead to validation testing in preclinical PDAC models. Combination therapy of iExoKrasG12D and anti-CTLA-4 antibodies, but not anti-PD1, revealed robust pre-clinical anti-tumor efficacy via FAS mediated CD8+ T cell anti-tumor activity. This first-in-human, precision medicine clinical trial and supporting preclinical functional studies offer new insights into priming of immunotherapy by oncogenic Kras inhibitor for future opportunistic combination therapy for PDAC patients. iExoKrasG12D are engineered exosomes for the delivery of siRNA targeting KRASG12D. Here the authors describe the results of a phase I trial of iExoKrasG12D in patients with metastatic pancreatic cancer, reporting safety and clinical activity, as well as immunological correlates informing on tumor immune microenvironment reprograming and future combination with immune checkpoint inhibitors.’

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-025-63718-2

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 GMP iExoKrasG12D preclinical safety and biodistribution. A Schematic representation of iExoKrasG12D GMP production. Conditioned media (CM) from mesenchymal stromal cells (MSC) cultured in GMP was centrifuged to remove debris, filtered through 0.2 μm filter, and ultracentrifuged. The exosomes pellet was resuspended, subjected to electroporation to incorporate siRNA targeting KRASG12D using a 1:1 ratio (by mass) of exosomal protein and siRNA, and evaluated using quality control (QC) analysis for size distribution (mean size <400 nm) and exosome surface detection of CD47 and CD63 by flow cytometry. B Representative picture of cryo-electron microscopy of GMP iExoKrasG12D. Scale bar: 100 nm. This experiment was performed once. C Schematic representation of a murine toxicology study using intravenous (i.v.) GMP iExoKrasG12D treatment (Rx) for three consecutive cycles. Each cycle represents two weeks (W1: week 1; W2: week 2, etc.) and three iExoKrasG12D treatments on days 1, 4, and 10. D Body weight measurements over time for the listed groups of mice, PT: pretreatment. 1X, 2X, and 4X exosomes reflect dosing corresponding to clinical trial dosing, see also Table 1, n = 10 mice per group. Data are presented as mean +/– SD. E Schematic representation of NHP toxicology study using intravenous (i.v.) GMP iExoKrasG12D treatment (Rx) for three consecutive cycles. Each cycle represents two weeks (W1: week 1; W2: week 2, etc.) and iExoKrasG12D treatments on the listed days, distributing three iExoKrasG12D treatments over the course of 2 weeks. F Body weight measurements over time for the listed NHP. For dosing details, see Table 1. G Schematic representation of NHP biodistribution study using intravenous (i.v.) or intraperitoneal (i.p.) GMP iExoKrasG12D that was labeled with PKH-67 or DiR dye. H, I Representative fluorescence images (H) of pancreas and liver sections from NHP following PKH-67+ iExoKrasG12D treatment and associated quantification (I) of the density of the ratio of PKH67 level over nuclear staining (DAPI) in the listed organs. Scale bar: 10 μm. This experiment was performed once. J Normalized relative luminescence unit (RLU) in the listed organs for the detection of DiR+ label following i.v. or i.p. DiR+ iExoKrasG12D treatment. CNS: central nervous system; GI: gastrointestinal; Med. oblongata: medulla oblongata; LN: lymph node. Data also presented in part in Supplementary Fig. 6B. Source data is provided as Source Data file.
Fig. 1 GMP iExoKrasG12D preclinical safety and biodistribution. A Schematic representation of iExoKrasG12D GMP production. Conditioned media (CM) from mesenchymal stromal cells (MSC) cultured in GMP was centrifuged to remove debris, filtered through 0.2 μm filter, and ultracentrifuged. The exosomes pellet was resuspended, subjected to electroporation to incorporate siRNA targeting KRASG12D using a 1:1 ratio (by mass) of exosomal protein and siRNA, and evaluated using quality control (QC) analysis for size distribution (mean size <400 nm) and exosome surface detection of CD47 and CD63 by flow cytometry. B Representative picture of cryo-electron microscopy of GMP iExoKrasG12D. Scale bar: 100 nm. This experiment was performed once. C Schematic representation of a murine toxicology study using intravenous (i.v.) GMP iExoKrasG12D treatment (Rx) for three consecutive cycles. Each cycle represents two weeks (W1: week 1; W2: week 2, etc.) and three iExoKrasG12D treatments on days 1, 4, and 10. D Body weight measurements over time for the listed groups of mice, PT: pretreatment. 1X, 2X, and 4X exosomes reflect dosing corresponding to clinical trial dosing, see also Table 1, n = 10 mice per group. Data are presented as mean +/– SD. E Schematic representation of NHP toxicology study using intravenous (i.v.) GMP iExoKrasG12D treatment (Rx) for three consecutive cycles. Each cycle represents two weeks (W1: week 1; W2: week 2, etc.) and iExoKrasG12D treatments on the listed days, distributing three iExoKrasG12D treatments over the course of 2 weeks. F Body weight measurements over time for the listed NHP. For dosing details, see Table 1. G Schematic representation of NHP biodistribution study using intravenous (i.v.) or intraperitoneal (i.p.) GMP iExoKrasG12D that was labeled with PKH-67 or DiR dye. H, I Representative fluorescence images (H) of pancreas and liver sections from NHP following PKH-67+ iExoKrasG12D treatment and associated quantification (I) of the density of the ratio of PKH67 level over nuclear staining (DAPI) in the listed organs. Scale bar: 10 μm. This experiment was performed once. J Normalized relative luminescence unit (RLU) in the listed organs for the detection of DiR+ label following i.v. or i.p. DiR+ iExoKrasG12D treatment. CNS: central nervous system; GI: gastrointestinal; Med. oblongata: medulla oblongata; LN: lymph node. Data also presented in part in Supplementary Fig. 6B. Source data is provided as Source Data file.CC BY-NC-ND · PubMed Central
Fig. 2 GMP iExoKrasG12D clinical trial design. A Schematic representation of dose escalation design. DL1: dose level 1; DL 2: dose level 2; etc. B CONSORT flow diagram adapted for the non-randomized Phase Ia trial. C CONSORT flow diagram adapted for the non-randomized Phase Ib trial. D Schematic representation of dosing schedule. PR/SD: partial response/stable disease; bx: biopsy. Tissue biopsy optional at end cycle 3in Phase Ib.
Fig. 2 GMP iExoKrasG12D clinical trial design. A Schematic representation of dose escalation design. DL1: dose level 1; DL 2: dose level 2; etc. B CONSORT flow diagram adapted for the non-randomized Phase Ia trial. C CONSORT flow diagram adapted for the non-randomized Phase Ib trial. D Schematic representation of dosing schedule. PR/SD: partial response/stable disease; bx: biopsy. Tissue biopsy optional at end cycle 3in Phase Ib.CC BY-NC-ND · PubMed Central
Fig. 3 GMP iExoKrasG12D in accelerated titration dosing design. Schematic representation of treatment timeline for patients in DL 4: dose level 4, DL 5: dose level 5, and DL5, and DL6: dose level 6, depicting prior therapy, timeframe for iExoKrasG12D therapy, and target lesion progression; scale bar listed. C1D1: Cycle 1 Day 1; C2D1: Cycle 2 Day 1; etc. QW: weekly; Dx: diagnosis; mo: month; Dt: death; [CT]: clinical trial; **: mutation analysis.
Fig. 3 GMP iExoKrasG12D in accelerated titration dosing design. Schematic representation of treatment timeline for patients in DL 4: dose level 4, DL 5: dose level 5, and DL5, and DL6: dose level 6, depicting prior therapy, timeframe for iExoKrasG12D therapy, and target lesion progression; scale bar listed. C1D1: Cycle 1 Day 1; C2D1: Cycle 2 Day 1; etc. QW: weekly; Dx: diagnosis; mo: month; Dt: death; [CT]: clinical trial; **: mutation analysis.CC BY-NC-ND · PubMed Central
Fig. 4 cfDNA and biopsy analyses. A Schematic representation of murine experimental timeline for tumor inoculation, IVIS imaging of tumor burden, and blood collection. B Relative level of KrasG12D cfDNA (expressed as a percent of KrasG12D copies over total Kras copies) in pre-treatment (pre-tx) and post-treatment (post-tx) with iExoKrasG12D and/or gemcitabine. Each line represents a distinct mouse per the listed experimental group: Control n = 6; iExoKrasG12D n = 4; gemcitabine n = 6; iExoKrasG12D + gemcitabine n = 7 mice. The data presented in panels A-B are analyses of blood samples from our earlier study19. C, D Relative level of KRASG12D cfDNA in the listed patients over time in the 3 + 3 (C) and accelerated dose titration (D) studies. PRE: pre-treatment; POST: post-treatment, with cycle definition at each time point evaluated. E. Representative H&E-stained tumor section from metastases in the abdominal wall (abdomen) or liver pre- and post-treatment with iExoKrasG12D. Scale bar:100 μm. This experiment was performed once. F Representative pERK-stained tumor section from metastases in the abdominal wall of S1D4, scale bar listed. This experiment was performed once. Source data is provided as Source Data file.
Fig. 4 cfDNA and biopsy analyses. A Schematic representation of murine experimental timeline for tumor inoculation, IVIS imaging of tumor burden, and blood collection. B Relative level of KrasG12D cfDNA (expressed as a percent of KrasG12D copies over total Kras copies) in pre-treatment (pre-tx) and post-treatment (post-tx) with iExoKrasG12D and/or gemcitabine. Each line represents a distinct mouse per the listed experimental group: Control n = 6; iExoKrasG12D n = 4; gemcitabine n = 6; iExoKrasG12D + gemcitabine n = 7 mice. The data presented in panels A-B are analyses of blood samples from our earlier study19. C, D Relative level of KRASG12D cfDNA in the listed patients over time in the 3 + 3 (C) and accelerated dose titration (D) studies. PRE: pre-treatment; POST: post-treatment, with cycle definition at each time point evaluated. E. Representative H&E-stained tumor section from metastases in the abdominal wall (abdomen) or liver pre- and post-treatment with iExoKrasG12D. Scale bar:100 μm. This experiment was performed once. F Representative pERK-stained tumor section from metastases in the abdominal wall of S1D4, scale bar listed. This experiment was performed once. Source data is provided as Source Data file.CC BY-NC-ND · PubMed Central
Fig. 5 Target engagement with iExoKrasG12D treatment. A, B Representative images of immunolabeling for pERK, PanCK, αSMA (A), with quantification of percentage of pERK+ panCK+ cancer cells (out of panCK+ cells) and αSMA+ pixels (B) in paired biopsies. This experiment was performed once. C, D Representative images (C), and quantification (D) of CD8+ T cells infiltrates in paired biopsies. Data are presented as mean. Scale bar:100 μm. Source data is provided as Source Data file.
Fig. 5 Target engagement with iExoKrasG12D treatment. A, B Representative images of immunolabeling for pERK, PanCK, αSMA (A), with quantification of percentage of pERK+ panCK+ cancer cells (out of panCK+ cells) and αSMA+ pixels (B) in paired biopsies. This experiment was performed once. C, D Representative images (C), and quantification (D) of CD8+ T cells infiltrates in paired biopsies. Data are presented as mean. Scale bar:100 μm. Source data is provided as Source Data file.CC BY-NC-ND · PubMed Central
Fig. 6 Synergy of iExoKrasG12D with anti-CTLA-4 for tumor suppression in preclinical studies. A Schematic of the experimental timeline using KTC GEM. iExoKrasG12D treatment was initiated at day 33 of age until day 44. B, C Representative images (B) and respective quantification (C) of CD4+ T cells (CD4), and CD8+ T cells (CD8) by immunolabeling in control and iExoKrasG12D treated KTC mice, n = 3 mice per group. D, E Representative images (D) and respective quantification (E) of CK19+ and Fas+ cells by immunolabeling in control and iExoKrasG12D treated mice, n = 3-4 mice per group. The data presented in panels A-E are analyses of tissues from our earlier study18. F Schematic of experimental timeline using orthotopic KPC mice. Treatment was initiated at day 12 post tumor implantation and mice euthanized 2 weeks post-treatment (day 26). G Tumor burden ((Pancreas or tumor weights/body weight) *100) of orthotopic KPC mice treated with iExoKrasG12D, control exosomes (CE), Isotypes control (Iso), αCTLA-4 and αPD-1, n = 5 mice per group. H, I Representative images (H), and quantification (I) of CK19 and pERK immunostainings in the indicated groups, n = 3-5 mice per group. J Representative image and respective quantification of CD8, CD19, CD31, and nuclear staining (DAPI) in tertiary lymphoid structure (TLS) in the tumors of mice in the indicated groups, n = 3-5 mice per group. Scale bar: 100 μm. Data are presented as mean +/– SD. Significance was determined by unpaired two-tailed t-test (C, E) or one-way ANOVA with Dunnett’s or Sidaak’s multiple comparisons test (G, I). nd: not detected; HPF, high-power filed; αCTLA-4, anti-CTLA-4; αPD-1, anti-PD-1. Source data is provided as Source Data file.
Fig. 6 Synergy of iExoKrasG12D with anti-CTLA-4 for tumor suppression in preclinical studies. A Schematic of the experimental timeline using KTC GEM. iExoKrasG12D treatment was initiated at day 33 of age until day 44. B, C Representative images (B) and respective quantification (C) of CD4+ T cells (CD4), and CD8+ T cells (CD8) by immunolabeling in control and iExoKrasG12D treated KTC mice, n = 3 mice per group. D, E Representative images (D) and respective quantification (E) of CK19+ and Fas+ cells by immunolabeling in control and iExoKrasG12D treated mice, n = 3-4 mice per group. The data presented in panels A-E are analyses of tissues from our earlier study18. F Schematic of experimental timeline using orthotopic KPC mice. Treatment was initiated at day 12 post tumor implantation and mice euthanized 2 weeks post-treatment (day 26). G Tumor burden ((Pancreas or tumor weights/body weight) *100) of orthotopic KPC mice treated with iExoKrasG12D, control exosomes (CE), Isotypes control (Iso), αCTLA-4 and αPD-1, n = 5 mice per group. H, I Representative images (H), and quantification (I) of CK19 and pERK immunostainings in the indicated groups, n = 3-5 mice per group. J Representative image and respective quantification of CD8, CD19, CD31, and nuclear staining (DAPI) in tertiary lymphoid structure (TLS) in the tumors of mice in the indicated groups, n = 3-5 mice per group. Scale bar: 100 μm. Data are presented as mean +/– SD. Significance was determined by unpaired two-tailed t-test (C, E) or one-way ANOVA with Dunnett’s or Sidaak’s multiple comparisons test (G, I). nd: not detected; HPF, high-power filed; αCTLA-4, anti-CTLA-4; αPD-1, anti-PD-1. Source data is provided as Source Data file.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 41 references

Cited by

See all 71

Metadata

Authors
Kalluri, V. S., Smaglo, B. G., Mahadevan, K. K., Kirtley, M. L., McAndrews, K. M., Mendt, M., Yang, S., Maldonado, A. S., Sugimoto, H., Salvatierra, M. E., Solis Soto, L. M., Haymaker, C., Finch, R., Gagea, M., Fluty, A. C., Ludtke, S. J., Jack Lee, J., Jain, A. K., Varadhachary, G., Shroff, R. T., Maitra, A., Shpall, E., Pant, S., & Kalluri, R.
Affiliations
  • The University of Texas MD Anderson Cancer Center (US)
  • Baylor College of Medicine (US)
  • University of Arizona Cancer Center (US)
Corresponding author
Kalluri, Valerie S.
Venue
Nature Communications
Published
2025-09-30
Volume
16
Issue
1
Pages
8696-8696
ISSN
2041-1723 (ISSN-L)
OpenAlex
W4414651339
Cited by
70
References
41
Citations by year
2026: 66 · 2025: 4
FWCI
20.92
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • Digital Commons-TMC (Texas Medical Center) (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Cancer Prevention and Research Institute of Texas (RP190602)
  • National Institutes of Health (1r35gm151999-01)
  • University of Texas MD Anderson Cancer Center
  • National Cancer Institute (R35CA263815)
  • National Institute of General Medical Sciences (R35GM151999, R01GM080139)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
Keywords
engineered exosomes, siRNA delivery, KRAS G12D, pancreatic ductal adenocarcinoma, exosome biodistribution, CD8+ T cells, tumor immune microenvironment, precision medicine, metastatic pancreatic cancer, safety and tolerability
MeSH terms
Aged, Animals, Female, Humans, Male, Middle Aged, Pancreatic Neoplasms, Proto-Oncogene Proteins p21(ras), CD8-Positive T-Lymphocytes, Carcinoma, Pancreatic Ductal, RNA, Small Interfering, Cell Line, Tumor, Mice, Exosomes

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Engineered exosomes with KrasG12D specific siRNA in pancreatic cancer: a phase I study with immunological correlates. https://app.cochat.ai/papers/10.1038/s41467-025-63718-2
The paper
Kalluri, V. S., Smaglo, B. G., Mahadevan, K. K., Kirtley, M. L., McAndrews, K. M., Mendt, M., Yang, S., Maldonado, A. S., Sugimoto, H., Salvatierra, M. E., Solis Soto, L. M., Haymaker, C., Finch, R., Gagea, M., Fluty, A. C., Ludtke, S. J., Jack Lee, J., Jain, A. K., Varadhachary, G., . . . Kalluri, R. (2025). Engineered exosomes with KrasG12D specific siRNA in pancreatic cancer: a phase I study with immunological correlates. Nature Communications. https://doi.org/10.1038/s41467-025-63718-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.